http://orcid.org/0000-0001-9182-3931
References
- Holmberg L, Maloney DG. The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma. J Natl Compr Canc Netw. 2011;9(9):1060–1071.
- Connors JM. State-of-the-art therapeutics: Hodgkin’s lymphoma. JCO. 2005;23(26):6400–6408.
- Anselmo AP, Cavalieri E, Meloni G, et al. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease. Haematologica. 2002;87(5):507–511.
- Majhail NS, Weisdorf DJ, Defor TE, et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2006;12(10):1065–1072.
- Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(8):1236–1243.
- Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
- Moskowitz CH, Walewski J, Nademanee A, et al. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse. Blood. 2018;132:2639–2642.
- Nademanee A, Sureda A, Stiff P, et al. Safety analysis of Brentuximab Vedotin from the phase III AETHERA trial in Hodgkin lymphoma in the post-transplant consolidation setting. Biol Blood Marrow Transplant. 2018;24(11):2354–2359.
- Hui L, von Keudell G, Wang R, et al. Cost-effectiveness analysis of consolidation with Brentuximab Vedotin for high-risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer. 2017;123(19):3763–3771.
- Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(19):1812–1821.
- Moskowitz C, Sweetenham J, Chen AI. Brentuximab vedotin after autologous stem cell transplant (ASCT) yields the strongest benefit in Hodgkin lymphoma (HL) patients with ≥2 risk factors: results of a multivariate analysis (MVA). JCO. 2016;1:1–80.